ReviewCritical Update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: A Systematic Analysis
Section snippets
Methods
We queried PubMed for articles published from January 1, 2010, through March 2, 2015, using the following search terms: (Testosterone/therapeutic use[MeSH terms] OR testosterone/deficiency [MeSH terms]) AND (cardiovascular OR morbidity OR mortality OR screening OR sexual function OR lower urinary tract symptoms OR obstructive sleep apnea OR prostate cancer OR fertility OR bone mineral density OR osteoporosis OR quality of life OR cognitive OR erectile dysfunction OR adverse effects). The date
Results
Of an original cohort of 462 abstracts, 26 articles (representing 17 trials) were selected for inclusion (Figure). The potential for bias was assessed and incorporated into the reported findings (Table).8 On the basis of these findings, we present a critical reassessment of several of the 2010 Guidelines as reflected by recent level 1a evidence trials and outlined herein.
Discussion
The 2010 Guidelines serve as a comprehensive and important tool for the evaluation and treatment of male hypogonadism. However, since their publication, several high-quality, level 1 studies examining contraindications, adverse events, and benefits of TRT have been published. These recent studies have examined specific populations underrepresented in the Guidelines, notably those with frailty and MetS.
There remain significant gaps in the literature, highlighted in the preceding systematic
Conclusion
A systematic analysis of level 1 evidence trials examining the safety and efficacy of TRT published since 2010 largely reinforces the Endocrine Society Guidelines. New trials indicate that severe LUTS and untreated OSA may not be absolute contraindications to TRT. Beneficial effects of TRT in men with MetS or frailty may be useful additions to future guideline recommendations. There is a lack of high-quality prospective trials examining the effects of TRT on CV morbidity.
Acknowledgment
AbbVie provided financial support for editorial assistance by Stephen Gutkin, Rete Biomedical Communications Corp (Wyckoff, NJ). The authors were not compensated for their roles in developing the manuscript. AbbVie did not conduct any review of the manuscript. The content and opinions expressed in the manuscript are solely those of the authors.
This systematic literature review was supported by AbbVie (North Chicago, IL).
References (38)
- et al.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
Int J Surg
(2010) - et al.
Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: a double-blind randomized controlled feasibility study
Am Heart J
(2012) - et al.
Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes
J Sex Med
(2013) - et al.
Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study
J Sex Med
(2014) - et al.
Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study
J Sex Med
(2010) - et al.
Treatment of hypogonadism with testosterone in patients with type 2 diabetes mellitus
Endocr Pract
(2010) - et al.
Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study)
J Sex Med
(2011) - et al.
Longitudinal effects of aging on serum total and free testosterone levels in healthy men
J Clin Endocrinol Metab
(2001) - et al.
Trends in androgen prescribing in the United States, 2001 to 2011
JAMA Intern Med
(2014) - et al.
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
J Clin Endocrinol Metab
(2010)
Rating the quality of evidence and the strength of recommendations using GRADE
World J Urol
Levels of evidence ratings in the urological literature: an assessment of interobserver agreement
BJU Int
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
BMJ
Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial
Clin Endocrinol (Oxf)
Obstructive sleep apnea: the effects of testosterone on ventilatory responses in men with obstructive sleep apnea : a randomised, placebo-controlled trial
J Sleep Res
Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels
J Clin Endocrinol Metab
Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial
Support. Care Cancer
Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty
J Gerontol A Biol Sci Med Sci
Cited by (0)
Potential Competing Interests: Dr Seftel is on the editorial board of the Journal of Urology; Dr Niederberger is a member of the American Urological Association Journal of Urology Urological Survey Editorial Committee, is the American Society of Reproductive Medicine co-editor-in-chief of Fertility and Sterility, is the founder and chief technology officer of NexHand, and has received research grant support from Ferring and IBSA.